Table 2.

Univariate analyses of TGFBI methylation in non-small cell lung cancer patients

Variable	Methylation status		P-value
	Absent	Present
Age (mean ± SD)	57.5 ± 8.4	60.0 ± 8.2	0.3037
Sex			0.4900
Male	26 (56.5%)	20 (43.5%)
Female	1 (25.0%)	3 (75.0%)
Pathological stage			0.8766
I	9 (50.0%)	9 (50.0%)
II	6 (50.0%)	6 (50.0%)
III	10 (62.5%)	6 (37.5%)
IV	2 (50.0%)	2 (50.0%)
Differentiation			0.3890
Well	1 (50.0%)	1 (50.0%)
Moderate	15 (48.4%)	16 (51.6%)
Poor	8 (57.1%)	6 (42.9%)
Unknown	3 (100.0%)	0 (0.0%)
Tumor size (cm) (mean ± SD)	4.19 ± 2.34	4.62 ± 2.62	0.6543
Tumor status			0.2946
T1	11 (61.1%)	7 (38.9%)
T2	12 (46.2%)	14 (53.8%)
T3	2 (66.7%)	1 (33.3%)
T4	1 (100.0%)	0 (0.0%)
Tx	2 (100.0%)	0 (0.0%)
Metastatic status			0.6871
Primary tumor	22 (61.1%)	14 (38.9%)
Lymph node metastasis	4 (40.0%)	6 (60.0%)
Distant metastasis	2 (50.0%)	2 (50.0%)
Histology			0.6614
Adenocarcinoma	14 (58.3%)	10 (41.7%)
Squamous cell carcinoma	12 (52.2%)	11 (47.8%)